Zealand Pharma

Director's Dealing • Mar 19, 2012

Copenhagen, 2012-03-19 13:21 CET (GLOBE NEWSWIRE) -- Company Announcement

No. 8/2012

Copenhagen, 19 March 2012 – Pursuant to the Danish Securities Trading Act,
section 28a, Zealand Pharma A/S shall announce transactions in the company’s
shares and related securities by executives and persons/companies closely
related to them.

In this regard, Zealand Pharma announces the following transaction:

Name: Christian Grøndahl

Reason: Executive Vice President and Chief Scientific
Officer

---

Issuer: Zealand Pharma A/S

Type Shares

ISIN code: DK0060257814

Transaction: Sale

Trading date: 15 and 16 March 2012

Market: NASDAQ OMX København A/S

Amount (number of shares): 60,000

Price: DKK 77.30

Market value: DKK 4,638,080

Christian Grøndahl now owns 160,413 shares and 98,031 warrants in Zealand
Pharma.

                                  ###

For further information, please contact:

David Horn Solomon, President and Chief Executive Officer

Tel: +45 2220 6300

Hanne Leth Hillman, Vice President for IR & Corporate Communication

Tel: +45 5060 3689, email: hlh@zealandpharma.com

About Zealand Pharma

Zealand Pharma A/S is a public (NASDAQ OMX: ZEAL) biotechnology company based
in Copenhagen, Denmark with a mature clinical pipeline of innovative peptide
drugs. The company's lead invention is lixisenatide (Lyxumia® 1)), a once-daily
GLP-1 agonist licensed to Sanofi for the treatment of Type 2 diabetes. In
October, Sanofi submitted a marketing authorization application (MAA) for
lixisenatide in Europe and submission for regulatory approval in the United
States is expected in Q4 2012. Zealand Pharma also has a collaboration with
Boehringer Ingelheim covering dual acting glucagon/GLP-1 agonists, including
ZP2929, for the treatment of diabetes and obesity, and a license agreement with
Helsinn Healthcare on elsiglutide, a clinical stage GLP-2 drug for the
prevention of chemotherapy-induced diarrhea.

Zealand Pharma specializes in the discovery, optimization and development of
novel peptide drugs, and all drug candidates in its pipeline have been
identified through the company's own drug discovery activities. Zealand
Pharma's products target disease areas where existing treatments fail to
adequately serve patient needs and where the market potential for improved
treatments through the use of peptide drugs is high.

For further information: www.zealandpharma.com.

Note 1) Lyxumia® is the intended trademark for lixisenatide. Lixisenatide is
not currently approved or licensed anywhere in the world.